This invention provides a method for diagnosing geriatric diseases
associated with insulin resistance, such as type II diabetes, at an early
stage and a method for monitoring the therapeutic effects of agents for
type II diabetes by quantitatively assaying GBP28 with the use of a
monoclonal antibody that can assay adiponectin (GBP28) in a sample.